OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 18 of 19

19 Weight Loss Interventions That Are Not Recommended   ➤ Human chorionic gonadotropin injections (HCG) combined with extreme diets have had some notoriety. No evidence substantiates the claim that HCG has an effect on weight beyond the caloric restriction in the "HCG diet".   ➤ Diuretics or laxatives may cause water loss. They can be dangerous and are not an obesity treatment.   ➤ Amphetamines (such as dextroamphetamine or methamphetamine) were used historically but have high abuse potential and are not appropriate for obesity management.   ➤ The FDA does not approve compounded drugs, thus the FDA cannot assure the safety, efficacy, or purity of compounded drugs. OTC Supplements and Alternative Weight-Loss Aids   ➤ A vast market of dietary supplements, herbal remedies, and OTC products claim to aid weight loss.   ➤ Clinicians should proactively inquire about any weight loss supplements patients may be using and provide education regarding realistic expectations and potential risks.   ➤ In summary, the current evidence does not support the recommendation of any herbal or over the counter supplements for substantial weight loss, and some may pose health risks. Potential Risks   ➤ "Natural" does not equal "safe." Serious adverse events have been linked to weight-loss supplements: • Cardiovascular: potentially fatal cardiac events • Hepatoxicity: acute liver injury • Nephrotoxicity: acute kidney injury • Adulteration: undeclared pharmaceuticals

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026